Cargando…

Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice

Microvascular failure is one of the key pathogenic factors in the dynamic pathological evolution after traumatic brain injury (TBI). Our laboratory and others previously reported that Annexin A2 functions in blood-brain barrier (BBB) development and cerebral angiogenesis, and recombinant human Annex...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chongjie, Wang, Xiaoshu, Jiang, Yinghua, Li, Yadan, Liao, Zhengbu, Li, Wenlu, Yu, Zhanyang, Whalen, Michael J., Lok, Josephine, Dumont, Aaron S., Liu, Ning, Wang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363504/
https://www.ncbi.nlm.nih.gov/pubmed/34400908
http://dx.doi.org/10.3389/fphar.2021.708469
_version_ 1783738367349882880
author Cheng, Chongjie
Wang, Xiaoshu
Jiang, Yinghua
Li, Yadan
Liao, Zhengbu
Li, Wenlu
Yu, Zhanyang
Whalen, Michael J.
Lok, Josephine
Dumont, Aaron S.
Liu, Ning
Wang, Xiaoying
author_facet Cheng, Chongjie
Wang, Xiaoshu
Jiang, Yinghua
Li, Yadan
Liao, Zhengbu
Li, Wenlu
Yu, Zhanyang
Whalen, Michael J.
Lok, Josephine
Dumont, Aaron S.
Liu, Ning
Wang, Xiaoying
author_sort Cheng, Chongjie
collection PubMed
description Microvascular failure is one of the key pathogenic factors in the dynamic pathological evolution after traumatic brain injury (TBI). Our laboratory and others previously reported that Annexin A2 functions in blood-brain barrier (BBB) development and cerebral angiogenesis, and recombinant human Annexin A2 (rA2) protected against hypoxia plus IL-1β-induced cerebral trans-endothelial permeability in vitro, and cerebral angiogenesis impairment of AXNA2 knock-out mice in vivo. We thereby hypothesized that ANXA2 might be a cerebrovascular therapy candidate that targets early BBB integrity disruption, and subacute/delayed cerebrovascular remodeling after TBI, ultimately improve neurological outcomes. In a controlled cortex impact (CCI) mice model, we found rA2 treatment (1 mg/kg) significantly reduced early BBB disruption at 24 h after TBI; and rA2 daily treatment for 7 days augmented TBI-induced mRNA levels of pro-angiogenic and endothelial-derived trophic factors in cerebral microvessels. In cultured human brain microvascular endothelial cells (HBMEC), through MAPKs array, we identified that rA2 significantly activated Akt, ERK, and CREB, and the activated CREB might be responsible for the rA2-induced VEGF and BDNF expression. Moreover, rA2 administration significantly increased cerebral angiogenesis examined at 14 days and vessel density at 28 days after TBI in mice. Consistently, our results validated that rA2 significantly induced angiogenesis in vitro, evidenced by tube formation and scratched migration assays in HBMEC. Lastly, we demonstrated that rA2 improved long-term sensorimotor and cognitive function, and reduced brain tissue loss at 28 days after TBI. Our findings suggest that rA2 might be a novel vascular targeting approach for treating TBI.
format Online
Article
Text
id pubmed-8363504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83635042021-08-15 Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice Cheng, Chongjie Wang, Xiaoshu Jiang, Yinghua Li, Yadan Liao, Zhengbu Li, Wenlu Yu, Zhanyang Whalen, Michael J. Lok, Josephine Dumont, Aaron S. Liu, Ning Wang, Xiaoying Front Pharmacol Pharmacology Microvascular failure is one of the key pathogenic factors in the dynamic pathological evolution after traumatic brain injury (TBI). Our laboratory and others previously reported that Annexin A2 functions in blood-brain barrier (BBB) development and cerebral angiogenesis, and recombinant human Annexin A2 (rA2) protected against hypoxia plus IL-1β-induced cerebral trans-endothelial permeability in vitro, and cerebral angiogenesis impairment of AXNA2 knock-out mice in vivo. We thereby hypothesized that ANXA2 might be a cerebrovascular therapy candidate that targets early BBB integrity disruption, and subacute/delayed cerebrovascular remodeling after TBI, ultimately improve neurological outcomes. In a controlled cortex impact (CCI) mice model, we found rA2 treatment (1 mg/kg) significantly reduced early BBB disruption at 24 h after TBI; and rA2 daily treatment for 7 days augmented TBI-induced mRNA levels of pro-angiogenic and endothelial-derived trophic factors in cerebral microvessels. In cultured human brain microvascular endothelial cells (HBMEC), through MAPKs array, we identified that rA2 significantly activated Akt, ERK, and CREB, and the activated CREB might be responsible for the rA2-induced VEGF and BDNF expression. Moreover, rA2 administration significantly increased cerebral angiogenesis examined at 14 days and vessel density at 28 days after TBI in mice. Consistently, our results validated that rA2 significantly induced angiogenesis in vitro, evidenced by tube formation and scratched migration assays in HBMEC. Lastly, we demonstrated that rA2 improved long-term sensorimotor and cognitive function, and reduced brain tissue loss at 28 days after TBI. Our findings suggest that rA2 might be a novel vascular targeting approach for treating TBI. Frontiers Media S.A. 2021-07-12 /pmc/articles/PMC8363504/ /pubmed/34400908 http://dx.doi.org/10.3389/fphar.2021.708469 Text en Copyright © 2021 Cheng, Wang, Jiang, Li, Liao, Li, Yu, Whalen, Lok, Dumont, Liu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cheng, Chongjie
Wang, Xiaoshu
Jiang, Yinghua
Li, Yadan
Liao, Zhengbu
Li, Wenlu
Yu, Zhanyang
Whalen, Michael J.
Lok, Josephine
Dumont, Aaron S.
Liu, Ning
Wang, Xiaoying
Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title_full Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title_fullStr Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title_full_unstemmed Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title_short Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
title_sort recombinant annexin a2 administration improves neurological outcomes after traumatic brain injury in mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363504/
https://www.ncbi.nlm.nih.gov/pubmed/34400908
http://dx.doi.org/10.3389/fphar.2021.708469
work_keys_str_mv AT chengchongjie recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT wangxiaoshu recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT jiangyinghua recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT liyadan recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT liaozhengbu recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT liwenlu recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT yuzhanyang recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT whalenmichaelj recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT lokjosephine recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT dumontaarons recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT liuning recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice
AT wangxiaoying recombinantannexina2administrationimprovesneurologicaloutcomesaftertraumaticbraininjuryinmice